FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890889727> ?p ?o ?g. }

• W2890889727 endingPage "2629" @default.
• W2890889727 startingPage "2623" @default.
• W2890889727 abstract "Local ablative treatment to oligometastatic patients can result in long-term disease-free survival in some cancer patients. The importance of this treatment paradigm in prostate cancer is a rapidly evolving field. Herein, we report on the safety and preliminary clinical outcomes of a modern cohort of oligometastatic prostate cancer (OPC) patients treated with consolidative stereotactic ablative radiation (SABR). Records of men with OPC who underwent consolidative SABR at our institution were reviewed. SABR was delivered in 1–5 fractions of 5–18 Gray. Kaplan–Meier estimates of local progression-free survival (LPFS), biochemical progression-free survival (bPFS; PSA nadir + 2), distant progression-free survival (DPFS), and time-to-next intervention (TTNI) were calculated. In total, 66 OPC patients were identified with consolidative SABR delivered to 134 metastases: 89 bone, 40 nodal, and 5 viscera. The majority of men (49/66) had hormone-sensitive prostate cancer (HSPC). Crude grade 1 and 2 acute toxicities were 36% and 11%, respectively, with no ≥ grade 3 toxicity. At 1 year, LPFS was 92% and bPFS and DPFS were 69%. Of the 18 men with HSPC who had deferred hormone therapy , 11 (56%) remain disease free following SABR (1-year ADT-FS was 78%). In 17 castration-resistant men, 11 had > 50% prostate-specific antigen (PSA) declines with 1-year TTNI of 30%. Consolidative SABR in OPC is feasible and well tolerated. The heterogeneity and small size of our series limit extrapolation of clinically meaningful outcomes following consolidative SABR in OPC, but our preliminary data suggest that this approach warrants continued prospective study." @default.
• W2890889727 created "2018-09-27" @default.
• W2890889727 creator A5001783218 @default.
• W2890889727 creator A5002414848 @default.
• W2890889727 creator A5006355538 @default.
• W2890889727 creator A5009222846 @default.
• W2890889727 creator A5011710591 @default.
• W2890889727 creator A5012074439 @default.
• W2890889727 creator A5013881851 @default.
• W2890889727 creator A5018645768 @default.
• W2890889727 creator A5023403037 @default.
• W2890889727 creator A5039646183 @default.
• W2890889727 creator A5054386630 @default.
• W2890889727 creator A5055949265 @default.
• W2890889727 creator A5061760121 @default.
• W2890889727 creator A5070623757 @default.
• W2890889727 creator A5071418753 @default.
• W2890889727 creator A5075913396 @default.
• W2890889727 creator A5080403309 @default.
• W2890889727 creator A5087520734 @default.
• W2890889727 date "2018-09-06" @default.
• W2890889727 modified "2023-10-04" @default.
• W2890889727 title "Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment" @default.
• W2890889727 cites W1499990855 @default.
• W2890889727 cites W1840588612 @default.
• W2890889727 cites W1891507428 @default.
• W2890889727 cites W2030227571 @default.
• W2890889727 cites W2069380387 @default.
• W2890889727 cites W2071241476 @default.
• W2890889727 cites W2100374144 @default.
• W2890889727 cites W2108168221 @default.
• W2890889727 cites W2115092415 @default.
• W2890889727 cites W2127240958 @default.
• W2890889727 cites W2131498353 @default.
• W2890889727 cites W2137314791 @default.
• W2890889727 cites W2139483106 @default.
• W2890889727 cites W2142138307 @default.
• W2890889727 cites W2148199505 @default.
• W2890889727 cites W2148867458 @default.
• W2890889727 cites W2183674768 @default.
• W2890889727 cites W2253196302 @default.
• W2890889727 cites W2268596702 @default.
• W2890889727 cites W2321373517 @default.
• W2890889727 cites W2403758065 @default.
• W2890889727 cites W2405616281 @default.
• W2890889727 cites W2507354747 @default.
• W2890889727 cites W2511755939 @default.
• W2890889727 cites W2519027667 @default.
• W2890889727 cites W2529888262 @default.
• W2890889727 cites W2536769127 @default.
• W2890889727 cites W2552482676 @default.
• W2890889727 cites W25596280 @default.
• W2890889727 cites W2747506142 @default.
• W2890889727 cites W2761351587 @default.
• W2890889727 cites W2773997734 @default.
• W2890889727 cites W2775321189 @default.
• W2890889727 cites W2780159205 @default.
• W2890889727 cites W2794422949 @default.
• W2890889727 cites W4240340450 @default.
• W2890889727 doi "https://doi.org/10.1007/s00345-018-2477-2" @default.
• W2890889727 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6401357" @default.
• W2890889727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30191396" @default.
• W2890889727 hasPublicationYear "2018" @default.
• W2890889727 type Work @default.
• W2890889727 sameAs 2890889727 @default.
• W2890889727 citedByCount "20" @default.
• W2890889727 countsByYear W28908897272019 @default.
• W2890889727 countsByYear W28908897272020 @default.
• W2890889727 countsByYear W28908897272021 @default.
• W2890889727 countsByYear W28908897272022 @default.
• W2890889727 crossrefType "journal-article" @default.
• W2890889727 hasAuthorship W2890889727A5001783218 @default.
• W2890889727 hasAuthorship W2890889727A5002414848 @default.
• W2890889727 hasAuthorship W2890889727A5006355538 @default.
• W2890889727 hasAuthorship W2890889727A5009222846 @default.
• W2890889727 hasAuthorship W2890889727A5011710591 @default.
• W2890889727 hasAuthorship W2890889727A5012074439 @default.
• W2890889727 hasAuthorship W2890889727A5013881851 @default.
• W2890889727 hasAuthorship W2890889727A5018645768 @default.
• W2890889727 hasAuthorship W2890889727A5023403037 @default.
• W2890889727 hasAuthorship W2890889727A5039646183 @default.
• W2890889727 hasAuthorship W2890889727A5054386630 @default.
• W2890889727 hasAuthorship W2890889727A5055949265 @default.
• W2890889727 hasAuthorship W2890889727A5061760121 @default.
• W2890889727 hasAuthorship W2890889727A5070623757 @default.
• W2890889727 hasAuthorship W2890889727A5071418753 @default.
• W2890889727 hasAuthorship W2890889727A5075913396 @default.
• W2890889727 hasAuthorship W2890889727A5080403309 @default.
• W2890889727 hasAuthorship W2890889727A5087520734 @default.
• W2890889727 hasBestOaLocation W28908897272 @default.
• W2890889727 hasConcept C106159729 @default.
• W2890889727 hasConcept C121608353 @default.
• W2890889727 hasConcept C126322002 @default.
• W2890889727 hasConcept C126894567 @default.
• W2890889727 hasConcept C143998085 @default.
• W2890889727 hasConcept C162324750 @default.
• W2890889727 hasConcept C187625094 @default.
• W2890889727 hasConcept C19617505 @default.

• next